A Phase 1/2, Open-Label Dose Escalation and Expansion Study of SNV4818 as Monotherapy or in Combination With Other Anticancer Agents in Participants With Advanced Solid Tumors
This study is testing an experimental medicine called SNV4818 to see how well it works against advanced solid tumors. Researchers are looking for the best dose to keep people safe while working to stop or shrink the cancer.
This trial is for adults with advanced solid tumors that have a specific genetic change called a PIK3CA mutation. Participants must have already tried standard treatments that either didn't work or caused side effects they couldn't tolerate.
You will receive either the new medication alone or in combination with other approved cancer therapies. Throughout the study, doctors will monitor your health closely to see how your body reacts to the treatment.
The study is currently recruiting patients at medical centers in Los Angeles, Boston, and Philadelphia. You can talk to your doctor to see if one of these locations is right for you.
- 1Tests a new medicine for cancers that have spread.
- 2Specifically focuses on tumors with the PIK3CA genetic mutation.
- 3Involves close medical monitoring to ensure patient safety.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.